It would be interesting to further identify the levels of TRKA and downstream signaling pathways of NGF before and after imatinib treatment in CML-sensitive and CML-resistant patients. This evidence concerns the gene NGF and chronic myelogenous leukemia, BCR-ABL1 positive.